What question did this study set out to answer?

This research aims to evaluate the clinical effectiveness and safety of P-PSMA-101 CAR-T cell therapy in treating prostate cancer.

June 19, 2026

Piggybacking Towards Progress for CAR-T Cell Therapy in Prostate Cancer

Key Points

This research aims to evaluate the clinical effectiveness and safety of P-PSMA-101 CAR-T cell therapy in treating prostate cancer.
First-in-class CAR-T therapy targeting PSMA was administered to patients.
Focused on stem cell memory T cell-enriched populations for treatment efficacy.
Utilization of a novel iCasp9 safety switch to manage toxicity.
Two patients demonstrated notable clinical activity with the therapy.
PSA50 responses varied, showing generally modest results.
Severe toxicities occurred but were effectively mitigated by the iCasp9 safety switch.

Abstract

P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effector-related toxicities were observed in some patients, a novel iCasp9 safety switch was largely effective in mitigating toxicity.

Perguntar à IA

Bookmark

Cite This Study

Lee et al. (Wed,) studied this question.

synapsesocial.com/papers/6a34df7565a5b0777af2e8c8 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-26-0959

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Perguntar à IA

Bookmark